Alto Neuroscience (Alto Neuroscience) Net Income From Continuing Operations : $-24.63 Mil (TTM As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Alto Neuroscience Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Alto Neuroscience's net income from continuing operations for the three months ended in Mar. 2024 was $-13.42 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2024 was $-24.63 Mil.

Alto Neuroscience Net Income From Continuing Operations Historical Data

The historical data trend for Alto Neuroscience's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alto Neuroscience Net Income From Continuing Operations Chart

Alto Neuroscience Annual Data

Trend

Dec21

Dec22

Dec23

Net Income From Continuing Operations

-9.19

-27.71

-36.31

Alto Neuroscience Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Net Income From Continuing Operations	Get a 7-Day Free Trial			-7.65	-7.28	-	-11.22	-13.42

Alto Neuroscience Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-24.63 Mil.

Alto Neuroscience (Alto Neuroscience) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alto Neuroscience Inc (NYSE:ANRO) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Alto Neuroscience Inc is a clinical stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and highly effective treatment options. the company currently consists of five clinical-stage assets initially targeting major depressive disorder and schizophrenia populations as identified by independent brain-based biomarkers.

Alto Neuroscience (Alto Neuroscience) Headlines

From GuruFocus

Steven Cohen's Point72 Asset Management Buys New Stake in Alto Neuroscience Inc

By GuruFocus Research • 02-08-2024